Fax: (206) 667-7983
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma†
Article first published online: 22 FEB 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 18, pages 4564–4570, 15 September 2012
How to Cite
Pollack, S. M., Jungbluth, A. A., Hoch, B. L., Farrar, E. A., Bleakley, M., Schneider, D. J., Loggers, E. T., Rodler, E., Eary, J. F., Conrad, III, E. U., Jones, R. L. and Yee, C. (2012), NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer, 118: 4564–4570. doi: 10.1002/cncr.27446
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
- Issue published online: 5 SEP 2012
- Article first published online: 22 FEB 2012
- Manuscript Accepted: 27 DEC 2011
- Manuscript Revised: 8 DEC 2011
- Manuscript Received: 12 SEP 2011
- cancer testis antigens
Myxoid/round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for >33% of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-ESO-1 is a cancer-testis antigen (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors.
The authors investigated the feasibility of targeting NY-ESO-1 in patients with MRCL by evaluating the prevalence of NY-ESO-1 expression in tumors using immunohistochemistry and quantitative reverse transcriptase-polymerase chain reaction analysis. NY-ESO-1–specific tumor recognition by NY-ESO-1–specific T-cells also was analyzed using a chromium release assay.
A search of the University of Washington Sarcoma Tissue Bank identified paraffin-embedded tumor samples from 25 patients with MRCL. NY-ESO-1 expression was observed in every MRCL tumor assessed (100%); in 18 tumors (72%), staining was homogenous. In all but 2 tumors, staining was sufficiently robust (2+) that such patients would be eligible for clinical trials of NY-ESO-1–directed therapy. By using NY-ESO-1 specific, CD8-positive T-cells, the in vitro sensitivity of myxoid liposarcoma cell lines to antigen-specific lysis was demonstrated.
The current results establish NY-ESO-1 as an important target antigen for the treatment of patients with MRCL. Cancer 2012. © 2012 American Cancer Society.
On the basis of its immunogenicity, the cancer-testis antigen NY-ESO-1 is considered to be among the most attractive antigens for immunotherapy. It has been targeted in several clinical studies, including several vaccine trials that have induced serologic, cluster of differentiation 4 (CD4)-positive, and CD8-positive T-cell responses. Delayed type hypersensitivity responses after NY-ESO-1 vaccination have been associated with long-term survival.1, 2 Objective clinical responses have been observed in patients with melanoma after vaccination against NY-ESO-1, including 1 complete response.3
NY-ESO-1 also has been successfully targeted in trials of antigen-specific adoptive T-cell therapy. For example, transfer of NY-ESO-1–specific CD4-positive cells has been used effectively to treat patients with metastatic melanoma.4 NY-ESO-1 also has been targeted using a class I T-cell receptor (TCR) retrovirally transfected into T cells,5 inducing complete responses in patients with melanoma. To date, there have been no known grade III or grade IV autoimmune toxicities associated with anti-NY-ESO-1 therapy.
NY-ESO-1, a member of the family of cancer testis antigens (CT antigens), was first discovered through serologic analysis in patients with esophageal cancer; subsequently, it was observed that NY-ESO-1 induced a strong cytotoxic T-cell response.6-8 CT antigens (also sometimes referred to as cancer germ-cell antigens), as their name implies, are expressed at the protein level in various malignant tumors and germ cells of the testis but not in other adult tissues.
Soft tissue sarcomas are a heterogeneous group of malignancies of mesenchymal origin with a poor prognosis in the metastatic setting and a median overall survival <1 year.9, 10 Liposarcomas account for approximately 10% to 20% of soft tissue sarcomas and can be classified into 3 subtypes, each with their own distinct clinical behavior: pleomorphic, well-/dedifferentiated, and myxoid/round cell liposarcoma (MRCL). MRCL accounts for 40% to 50% of liposarcomas and is almost always associated with a chromosomal translocation, most commonly t(12;16)(q13;p11), although several less common translocations also have been described.11 The resultant fusion proteins have an activity that is not well understood.12 MRCL is relatively sensitive to frontline chemotherapy, and trabectedin as second-line treatment for metastatic MRCL is promising.10, 13 However, mortality remains high for patients with metastatic disease, suggesting the need for novel approaches.
The discovery that >80% of synovial sarcomas express NY-ESO-1,14 often homogenously, established synovial sarcoma as a malignancy with 1 of the highest rates of NY-ESO-1 expression and led to the perception that synovial sarcoma is a model disease for the study of NY-ESO-1–directed therapy. Supporting this concept, a recently published adoptive therapy trial5 using retrovirally transfected, NY-ESO-1–specific TCR, documented 4 partial responses in 6 patients with synovial sarcoma. Here, we report that another soft tissue sarcoma subtype, MRCL, ubiquitously expresses the cancer-testis antigen NY-ESO-1, most often homogenously, raising the possibility of NY-ESO-1–directed therapy for patients with this challenging disease, for whom there are limited treatment options in the metastatic setting.
MATERIALS AND METHODS
Both paraffin-embedded and flash-frozen samples from patients with MRCL were obtained through the University of Washington sarcoma tumor bank (Institutional Review Board-approved protocol 21369).
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues. The monoclonal antibody E978 was used to detect NY-ESO-1, as previously described.15 For all assays, appropriate positive controls (normal testis with preserved spermiogenesis) and negative controls (omission of primary antibody and replacement with phosphate buffer saline, pH 7.4) were included.
Tissue sections were deparaffinized in xylene and rehydrated in a series of graded alcohols. Endogenous peroxidase was blocked by incubating slides for 30 minutes at room temperature in 99.7% methanol containing 0.3% hydrogen peroxide. Slides were washed with Tris-buffered saline solution and blocked in 2% bovine serum albumin at room temperature for 5 minutes to prevent unspecific protein interactions. We used a heat-based antigen-retrieval technique with a commercial vegetable steamer to heat the slides in a buffer solution for 30 minutes at approximately 96°C. Tissue slides were incubated with primary antibodies overnight at 4°C in a wet chamber. Primary antibody detection was performed by using of a Novolink polymer detection kit (Leica Microsystems Inc., Bannockburn, Ill) according to the manufacturer's instructions. 3,3′-Diaminobenzidine served as a chromogen, and counterstains were done with Harris hematoxylin. Finally, slides were dehydrated in a series of graded ethanols and coverslipped.
The slides were examined under a light microscope by 2 pathologist, including an experienced bone and soft tissue pathologist. Characteristic morphologic features of myxoid liposarcoma were confirmed, including myxoid stroma, primitive mesenchymal cells, lipoblasts, and an arborizing capillary vasculature. Samples that had staining present in <5% of cells were considered focally positive. The presence of staining in 5% to 25% of cells was considered 1+ staining, the presence of staining in 25% to 50% of cells was considered 2+ staining, the presence of staining in 50% to 75% of cells was considered 3+ staining, and the presence of staining in >75% of cells was considered 4+ staining.
Quantitative Reverse Transcriptase-Polymerase Chain Reaction Analysis
RNA was extracted from frozen tumor samples using Trizol (Invitrogen Life Technologies, Carlsbad, Calif) and from cell lines using the RNeasy kit (Qiagen, Valencia, Calif). Because of various tissue-collection conditions, RNA quality was recorded before analysis using either a gel or a bioanalyzer. Samples with poor-quality RNA were not analyzed further. One nonmyxoid liposarcoma sample was invading into the spermatic cord and, thus, was not included in the analysis because of concerns about a false-positive result.
RNA samples were converted to combinational DNA (cDNA) using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Indianapolis, Ind). The results were analyzed using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a housekeeping gene and were calculated relative to testis using the standard curve method. The NY-ESO-1 primers were TGCTTGAGTTCTACCTGCCA and TATGTTGCCGGACACAGTGAA.16 GAPDH primers were GAAGGTGAAGGTCGGAGTC and GAAGATGGTGATGGGATTTC.17 In all MRCL tumors, NY-ESO-1 expression also was confirmed and quantified using primers from SA Biosciences (Frederick, Md). Amplification was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, Calif) on an ABI 7900HT (Applied Biosystems).
NY-ESO-1–specific effectors were generated from a patient with human leukemic antigen (HLA) A*0201 (HLA-A*0201)-positive synovial sarcoma who underwent leukopheresis according to established protocols (Fred Hutchinson Cancer Research Center, Protocol 1246). Peripheral blood mononuclear cell (PBMC)-derived dendritic cells18 were pulsed with the NY-ESO-1 peptide SLLMWITQC. PBMCs were depleted of CD25-positive T-cells using CliniMACS CD25 MicroBeads (Miltenyi Biotech, Auburn, Calif) according to manufacturer's instructions and were stimulated using interleukin 21 as previously described.19 NY-ESO-1–positive cells were sorted using NY-ESO-1 tetramer, then cloned with limited dilution, and expanded using a rapid expansion protocol.20 T-cell clones that were specific for melanoma antigen recognized by T-cells (MART-1) were used as control effector cells.
The human myxoid liposarcoma cell lines 402 and 1765 (gifts of Pierre Aman) have been described previously.21 They were maintained in RPMI 1640 medium containing 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2 mM L-glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin (Invitrogen) in 10% fetal bovine serum. The T2 cell line—a peptide transporter (TAP)-deficient T–B-cell hybrid that expresses the HLA-A2 allele—was used unpulsed as a negative control and was pulsed with target peptide as a positive control.
Chromium Release Assay Using Recombinant Vaccinia–HLA-A2–Transfected Targets
Because the target cells (cell lines 402 and 1765) did not express HLA-A*0201, we used recombinant vaccinia to endow target cells with the presenting HLA-restricting element according to established methods.22 The NY-ESO-1–positive MRCL tumor lines 402 and 1765 were transfected with the HLA-A*0201 gene using a vaccinia vector at a multiplicity of infection (MOI) of 2.5, which was identified as the optimal MOI in titration experiments. For a control against cell lysis resulting from the vaccinia infection, the cell lines also were treated with wild-type Vaccinia virus. For the chromium release assay, cell lines were labeled with 100 μCi 51Cr and cocultured with effector cells for 4 to 6 hours at 37°C in a 5% CO2 atmosphere.
Myxoid/Round Cell Liposarcoma Samples Expressed NY-ESO-1 in 100% of Samples, and Homogenous Expression Was Observed in >70% of Patients
We stained 25 MRCL tumors for NY-ESO-1, and all were positive for NY-ESO-1 expression. In 2 tumors, only 1+ staining was observed (5%-25% of cells were positive for staining). In the remaining 23 tumors, at least 2+ staining was observed (2+ staining has been the cutoff for clinical trial eligibility in some trials of NY-ESO-1–directed therapy5). In 6 of 25 tumors, flash-frozen tissue was available for RNA extraction and quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis. In all of these tissues, NY-ESO-1 expression was confirmed (Table 1).
|Patient||Cytogenetics||Site of Primary Tumor||Primary or Metastatic Specimen||Outcome||NY-ESO-1 Staininga||qRT-PCR Confirmed|
|1||Unavailable||Right thigh||Primary||Metastatic Disease, died||3+||Not available|
|2||Unavailable||Right hip||Primary||Metastatic disease||3+||Not available|
|3||Unavailable||Left buttock||Primary||Local recurrence, currently disease free||3+||Not available|
|4||Unavailable||Right thigh||Metastatic||Metastatic disease||2+||Yes|
|5||Unavailable||Left popliteal fossa||Primary||Metastatic disease, died||4+||Not available|
|6||t(12;16) With other complex cytogenetics||Right groin||Primary||Metastatic disease, died||4+||Not available|
|7||t(12;16)(q13;p11)||Left popliteal fossa||Primary||Disease free||1+||Not available|
|8||t(12;16) With other complex cytogenetics||Left thigh||Primary||Metastatic disease, died||3+||Not available|
|9||t(10;16;12)(q26;p11;q13)||Left calf||Primary||Disease free||2+||Not available|
|10||Unavailable||Right thigh||Primary||Disease free||4+||Not available|
|11||t(12;16)(q13;p11)||Right thigh||Primary||Local recurrence, currently disease free||2+||Not available|
|12||t(12;16)(q13;p11)||Right thigh||Primary||Isolated recurrence, currently disease free||4+||Not available|
|13||t(12;16)(q13;p11)||Left popliteal fossa||Primary||Disease free||3+||Yes|
|14||t(12;16) With other complex cytogenetics||Right tibia||Primary||Disease free||4+||Not available|
|15||t(12;16)(q13;p11)||Right thigh||Primary||Disease free||4+||Not available|
|16||t(12;22)(q13;q12)||Right great toe||Primary||Disease free||2+||Not available|
|17||Unavailable||Left leg||Metastatic||Metastatic disease||4+||Not available|
|18||t(12;16) With other complex cytogenetics||Right thigh||Primary||Disease free||1+||Not available|
|19||t(12;16)(q13;p11)||Right pelvis||Primary||Metastatic disease||4+||Not available|
|20||Normal||Left thigh||Metastatic||Metastatic disease||3+||Not available|
|21||t(12;16) With other complex cytogenetics||Left axilla||Primary||Disease free||4+||Yes|
|22||t(12;16)(q13;p11)||Left gluteal||Primary||Metastatic disease||3+||Not available|
|23||t(15;17)(q22;q23)||Left thigh||Primary||Disease free||3+||Yes|
|24||t(12;16)(q13;p11)||Right thigh||Primary||Disease free||3+||Yes|
|25||t(12;16) With other complex cytogenetics||Left ankle/fibula||Primary||Metastatic disease||2+||Yes|
In 18 of 25 tumors (72%), staining was homogenous (3+ or 4+), ie, staining was observed in >50% of the tumor. Nine of these tumors had 4+ staining. In all but 3 tumors, the primary tumor was stained from a resection specimen; however, in the 3 tumors from patients who had metastatic disease, staining appeared to have at least similar pattern of expression (4+ staining in 2 tumors, 2+ staining in 1 tumor). At least 11 patients subsequently developed metastatic disease (several patients were lost to follow-up), but we were unable to observe a clear correlation between disease outcome and staining intensity.
It is noteworthy that, although most patients had the classic t(12;16)(q13;p11) translocation, there were 4 patients with different cytogenetics, including t(10;16;12), t(12;22), t(15;17), and 1 patient with normal cytogenetics (for that patient, the evaluation was repeated and confirmed, and the growth of normal host cells could not be excluded). All of these patients had NY-ESO-1 staining regardless of karyotype.
To determine whether NY-ESO-1 expression was limited to the MRCL subtype, we tested 7 nonmyxoid liposarcoma specimens using immunohistochemistry and also tested frozen samples from 3 (additional) patients by qRT-PCR. These 10 tumors included 2 pleomorphic liposarcomas, 4 well differentiated tumors, and 4 dedifferentiated tumors. None of these tumors expressed NY-ESO-1. Although these negative results are not definitive, they do suggest that the high prevalence of NY-ESO-1 expression observed in MRCL tumors is not shared among the other liposarcoma subtypes.
It is noteworthy that, although both myxoid and round cell areas of the tumor tended to stain positive for NY-ESO-1, a more uniform and intense appearance of the staining was observed in the round cell component. Also of interest was that the well differentiated elements of some tumors stained less homogenously (1+ to 2+) than the more typical myxoid and round cell components within the same tumor (Fig. 1).
Myxoid/Round Cell Liposarcoma Cell Lines Expressing NY-ESO-1 Can Be Recognized and Specifically Lysed by NY-ESO-1–Specific Effectors
The MRCL cell lines 402 and 1765 were analyzed by quantitative PCR, and NY-ESO-1 messenger RNA transcripts were expressed at levels even higher than those observed in testis normalized to GAPDH (2.5-fold and 3.5-fold higher). Both cell lines underwent class I typing at the Puget Sound Blood Center and were negative for HLA-A*02. Because HLA-A2–restricted, NY-ESO-1–specific cytotoxic T-lymphocytes were used to evaluate antigen recognition, the 402 and 1765 cells were preinfected with a recombinant Vaccinia virus that expressed HLA-A*0201 (Vac-A2). When treated with Vac-A2, the cells were lysed at >30% after 4 hours with an effector-to-target ratio of 20:1. Control MART-1–specific effectors were unable to kill either cell line. Similarly, MRCL cell lines transfected with wild-type Vaccinia virus were not sensitized to lysis by NY-ESO-1–specific effectors (Fig. 2).
NY-ESO-1 is widely considered an attractive target for immunotherapy. Complete responses have been observed in melanoma trials that targeted NY-ESO-1 using both vaccines as well as adoptively transferred T-cells. The discovery that 80% of synovial sarcomas express NY-ESO-1 was rapidly translated into a clinical trial; the National Cancer Institute surgery branch treated 6 patients with synovial sarcoma using T-cells transfected with a retrovirus that expressed the NY-ESO-1 TCR. Partial responses were observed in 4 of 6 synovial sarcoma patients.3-5
Here, we report another soft tissue sarcoma subtype that demonstrates a pattern of NY-ESO-1 expression that is even more prevalent than the pattern observed in synovial sarcoma. Although other reports have included NY-ESO-1 expression in liposarcomas, including MRCL, generally, this is the first study to specifically examine NY-ESO-1 protein expression in MRCL.23-28 On the basis of our analysis of 25 samples, MRCL appears to express NY-ESO-1 with a frequency that is unmatched by any other malignancy studied to date. Furthermore, a high proportion (9 of 25 tumors) had 4+ staining (>75% of cells), and an additional 9 of 25 tumors had 3+ staining (>50% of cells). It is noteworthy that patients who had histopathologic phenotypes of MRCL that included a variety of chromosomal translocations were included in this analysis, and all had tumors that expressed NY-ESO-1. Furthermore, we demonstrated that MRCL cell lines are capable of presenting NY-ESO-1 peptide, such that it can be recognized by NY-ESO-1–specific effectors in vitro initiating cell-mediated lysis of tumor cells.
MRCL generally is associated with a characteristic fusion protein; however, the role played by the mutation in oncogenesis is not clear. Most tumors contain t(12;16) (q13;p11), producing the fused in sarcoma (FUS)-C/EBP homologous protein (FUS-CHOP) fusion protein, although a notable minority contains t(12;22)(q13;12) translocation-associated Ewing sarcoma (EWS) breakpoint region 1 (EWSR1)-CHOP. Both FUS and EWS (along with TF15 RNA polymerase II, TATA box binding protein-associated factor [TAF15]) are in the FET family (also known as the TET family) of RNA binding proteins.29 However, although the RNA binding profiles of the FET family proteins are remarkably similar to one another,30 Ewing sarcomas, which typically have translocations of EWS,31, 32 do not generally express NY-ESO-1.33
There is evidence to suggest that murine adipocyte-derived mesenchymal stem cells transfected with a FUS-CHOP gene develop an MRCL phenotype; however, the translocation alone was insufficient to induce an MRCL tumor-like phenotype using human adipocyte-derived mesenchymal stem cells transfected with FUS-CHOP, suggesting the need for additional genetic “hits.”34-37 Similar to MRCL, in synovial sarcoma models, the presence of synovial sarcoma translocation t(X;18) (SYT-SSX) alone appears to be insufficient on its own to cause oncogenesis.38 Mesenchymal stem cells also have been postulated as potential cells of origin in synovial sarcoma.39
To our knowledge, there has never been a study of NY-ESO-1–specific serologic response in patients with MRCL.28, 40 An analysis of the serologic response to several CT antigens, including NY-ESO-1, was reported in 54 patients with sarcoma, including 5 patients with synovial sarcoma and 1 patient with MRCL. In that report, serology was negative except for 2 patients (1 with pleomorphic sarcoma and another with fibrosarcoma).41 Serology was also analyzed in a study by Ayyoub et al that included 1 patient with liposarcoma, although the histologic subtype was not mentioned.28
The expression of CT antigens has been correlated with outcomes in several malignancies.42-44 Although the numbers in our current study would be under powered to perform an adequate analysis assessing differences in outcome patterns between patients with strong and weak NY-ESO-1 expression, we are assessing the feasibility of this approach in our patient population. We also are assessing ways to apply this knowledge to preclinical models, such as MRCL xenografts, to advance NY-ESO-1–directed immunotherapy for patients with sarcoma.45
To our knowledge, no other malignancy, including synovial sarcoma, has been described that has NY-ESO-1 expression in 100% of tumors or such a high proportion homogenous expression. We believe that, like synovial sarcoma, these results will establish MRCL as a model disease for the study of NY-ESO-1–directed therapy.
This work is supported by the Bob and Eileen Gilman Family Sarcoma Research Program as well as the Walker Immunotherapy Research Fellowship and the Sarcoma Alliance for Research Through Collaboration (SARC) Career Development Award. The University of Washington Tissue Bank is supported by grant RO1 CA65537-16. Seth M. Pollack is a recipient of the SARC Career Development Award as well as the Walker Immunotherapy Research Fellowship. Marie Bleakley is the Damon Runyon-Richard Lumsden Foundation Clinical Investigator and is supported in part by the Damon Runyon Cancer Research Foundation (CI-57-11) and in part by K23CA154532-01 from the National Cancer Institute. Eve Rodler is supported by Abbott Laboratories. Janet F. Eary is supported grant RO1 CA65537-16. Robin L. Jones is supported by the Bob and Eileen Gilman Family Sarcoma Research Program. Cassian Yee is a recipient of a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.
CONFLICT OF INTEREST DISCLOSURES
The authors made no disclosures.
- 9Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13: 1537-1545., , , et al.
- 11Liposarcoma: molecular genetics and therapeutics [serial online]. Sarcoma 2011: 483154, 2011., , .
- 23Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics [serial online]. Cancer Immun. 2005; 5: 2., , , et al.
- 28The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma [serial online]. Cancer Immun. 2004; 4: 7., , , et al.
- 44Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients [serial online]. Cancer Immun. 2010; 10: 4., , , et al.